Autopsy report · NCT02157272

Rivaroxaban in Thrombotic Antiphospholipid Syndrome

“Unbalance in the composite endpoint between arms.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 121 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University of Padova

Sponsor type

University, hospital or other

Conditions

Antiphospholipid Syndrome

Interventions

Experimental: Rivaroxaban

Participants

121

Sites

1

Countries

Italy

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.